mm study at the University of Iceland I also work as a medical doctor at the department of hematology at Rick's hospitality and Copenhagen Denmark my abstracted ass was circulating tumor plasma cells in the screen isotopamine smoldering multiple myeloma cohort and these are my co-authors now evaluation of circulating tumor plasma cells in peripheral blood has been associated with risk of progression from smoldering myeloma to multiple myeloma circulating tumor plasma cells May therefore be a mar
ker for two month Burton or tumor aggressiveness and smoldering myeloma the Dynamics of circulating tumor plasma cells between risk categories in a screen cohort of individuals with smoldering myeloma has not been studied the aims of the study were to investigate the detection and quantification of circulating tumor plasma cells and individuals with smoldering myeloma diagnosed in the screen by step mm study we wanted to compare the findings and smoldering myeloma to mgus and multiple myeloma an
d to associate the Fine Things in smoldering myeloma to known clinical risk models of progression to multiple myeloma we included individuals with motoring myeloma and Gus and multiple myeloma we perform Next Generation flow cytometry to assess circulating tumor plasma cells numbers in peripheral blood we set a limit of detection at 20 tumor plasma cells I found an optimal cut-off value to discriminate between smoldering myeloma and multiple myeloma and then we we found the difference in frequen
cy of circulating tumor plasma cells between risk groups according to the pythmia risk stratification model and the Mayo Clinic to 2020 risk certification models and between amgos smoldering myeloma and multiple myeloma patients now to the results the percentage of circulating tumor plasma cells increased from Amicus to smoldering myeloma to multiple myeloma and so did the median percentage of circulating tumor plasma cells and those that were above the cutoff value the percentage of those that
were above the cutoff value also increased from M gusts the smoldering myeloma to multiple myeloma when we stratified the smoldering myeloma patients according to risk of progression uh in the Mayo 2 2020 model we saw that the percentage where we found circulating tumor plasma cells increased from the low risk to the intermediate and to the high-risk groups however when we found the median circular and tumor plasma cells percentage in those were circulating tumor plasma cells were detected it di
d not increase significantly from the low risk to the intermediate risk to the high-risk groups um and neither did the percentage above the cutoff when we stratified the patients according to the pathima risk stratification model we found that the risk that the percentage of circulating tumor plasma cells detected increased from the low risk to the intermediate and high-risk groups and this was significant and the median circulating tumor plasma cells were similar in the groups but those that we
re above the cutoff in the percent that's increased from the low risk to the intermediate and to the high-risk groups and here you can see a figure of the percentage of circulating tumor plasma cells on the left in amcus smoldering myeloma and multiple myeloma and the dotted line represent the the cutoff value that we found between smoldering myeloma and multiple myeloma and then the middle and on the right side you can see uh the low risk intermediate risk and high risk groups of smoldering mye
loma patients and this seems to to differentiate between the low-risk groups and the intermediate to high-risk groups but there's not a lot of difference between the intermediate and high-risk groups perhaps because there are a few patients in the high-risk groups now in conclusion circulating tumor plasma cells are present and 69 of the overall population with smoldering myeloma in our screen cohort both the detection and numbers are circulating tumor plasma cells increased progressively from M
gusts to smoldering myeloma to multiple myeloma and we observed a similar Trend with increasing risk scores and these known risk stratification models but we don't have information about the risk of progression in these individuals yet these results indicate that next Generation flow of peripheral blood to detect circulating tumor plasma cells might have a role in the management of smoldering myeloma however future studies with serial monitoring or circulating tumor plasma cells are needed to f
urther Define the clinical value and if we can use this variable this would focus clinical care and treatments as smoldering myeloma and multiple myeloma to those who benefit the most from them we're limiting interventions and those who do not need them because this is an analysis of peripheral blood and maybe this can help in reducing the number of bone marrow biopsies that are needed so thank you [Music]
Comments